0.0438
전일 마감가:
$0.0534
열려 있는:
$0.0516
하루 거래량:
112.45M
Relative Volume:
4.10
시가총액:
$2.48M
수익:
-
순이익/손실:
$-33.44M
주가수익비율:
-0.00273
EPS:
-16.0242
순현금흐름:
$-28.30M
1주 성능:
+4.29%
1개월 성능:
-95.17%
6개월 성능:
-97.06%
1년 성능:
-98.81%
Nucana Plc Adr Stock (NCNA) Company Profile
NCNA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NCNA
Nucana Plc Adr
|
0.0438 | 254.39K | 0 | -33.44M | -28.30M | -16.02 |
![]()
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2022-03-03 | 다운그레이드 | Cowen | Outperform → Market Perform |
2020-10-22 | 개시 | Truist | Buy |
2020-07-24 | 개시 | Oppenheimer | Outperform |
2019-08-19 | 개시 | H.C. Wainwright | Buy |
2018-10-19 | 개시 | Piper Jaffray | Overweight |
2017-10-23 | 개시 | Citigroup | Buy |
2017-10-23 | 개시 | Jefferies | Buy |
2017-10-23 | 개시 | William Blair | Outperform |
모두보기
Nucana Plc Adr 주식(NCNA)의 최신 뉴스
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
NuCana prices $7 million direct offering of ADSs and warrants By Investing.com - Investing.com India
New Outlook On NuCana plc ADR - Stocksregister
NCNA’s Stock Journey: What Investors Need to Know About NuCana plc ADR’s Performance - investchronicle.com
Do investors need to be concerned about Cadiz Inc (CDZI)? - uspostnews.com
Natera Inc (NTRA) deserves closer scrutiny - uspostnews.com
Weave Communications Inc (WEAV) produces promising results - uspostnews.com
Investing in NuCana plc ADR (NCNA) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Nasdaq
Post-Trade Analysis: NuCana plc ADR (NCNA) Slides -26.97, Closing at 0.65 - DWinneX
Closing Bell Recap: Yxt.Com Group Holding Ltd. ADR (YXT) Ends at 0.56, Reflecting a -14.42 Downturn - DWinneX
In the Green: Gogoro Inc (GGR) Closes at 0.26, Up/Down 0.08 from Previous Day - DWinneX
Daily Market Movement: Tivic Health Systems Inc (TIVC) Sees a 1.88 Increase, Closing at 7.04 - DWinneX
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Barchart.com
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana plc Announces Reverse ADS Split - TipRanks
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Yahoo Finance
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session - Yahoo Finance
Will NuCana Continue to Surge Higher? - Nasdaq
NCNA Stock Price and Chart — NASDAQ:NCNA - TradingView
NuCana PLC Stock Price Today | NASDAQ: NCNA Live - Investing.com
Nucana Plc Adr (NCNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):